Efficacy and future prospects of commercially available and experimental vaccines against porcine circovirus type 2 (PCV2)
- PMID: 22005075
- DOI: 10.1016/j.virusres.2011.09.041
Efficacy and future prospects of commercially available and experimental vaccines against porcine circovirus type 2 (PCV2)
Abstract
Porcine circovirus type 2 (PCV2) is the causative agent of an economically significant collection of disease syndromes in pigs, now known as porcine circovirus associated diseases (PCVADs) in the United States or porcine circovirus diseases (PCVDs) in Europe. Inactivated and subunit vaccines based on PCV2a genotype are commercially available and have been shown to be effective at decreasing mortality and increasing growth parameters in commercial swine herds. Since 2003, there has been a drastic global shift in the predominant prevalence of PCV2b genotype in swine populations, concurrently in most but not all cases with increased severity of clinical disease. Although the current commercial vaccines based on PCV2a do confer cross-protection against PCV2b, novel experimental vaccines based on PCV2b genotype such as modified live-attenuated vaccines are being developed and may provide a superior protection and reduce vaccine costs. In this review, we discuss the current understanding of the impact of PCV2 infection on the host immune response, review the efficacy of the currently available commercial PCV2 vaccines in experimental and field conditions, and provide insight into novel experimental approaches that are useful in the development of next generation vaccines against PCV2.
Copyright © 2011 Elsevier B.V. All rights reserved.
Similar articles
-
An experimental live chimeric porcine circovirus 1-2a vaccine decreases porcine circovirus 2b viremia when administered intramuscularly or orally in a porcine circovirus 2b and porcine reproductive and respiratory syndrome virus dual-challenge model.Microbiol Immunol. 2011 Dec;55(12):863-73. doi: 10.1111/j.1348-0421.2011.00385.x. Microbiol Immunol. 2011. PMID: 21951266
-
A PCV2 vaccine based on genotype 2b is more effective than a 2a-based vaccine to protect against PCV2b or combined PCV2a/2b viremia in pigs with concurrent PCV2, PRRSV and PPV infection.Vaccine. 2013 Jan 7;31(3):487-94. doi: 10.1016/j.vaccine.2012.11.030. Epub 2012 Nov 19. Vaccine. 2013. PMID: 23174198
-
Comparative efficacy of experimental inactivated and live-attenuated chimeric porcine circovirus (PCV) 1-2b vaccines derived from PCV1 and PCV2b isolates originated in China.Virol J. 2015 Jul 30;12:113. doi: 10.1186/s12985-015-0338-9. Virol J. 2015. PMID: 26220290 Free PMC article. Clinical Trial.
-
Genetic variation of porcine circovirus type 2 (PCV2) and its relevance to vaccination, pathogenesis and diagnosis.Virus Res. 2012 Mar;164(1-2):68-77. doi: 10.1016/j.virusres.2011.11.018. Epub 2011 Dec 17. Virus Res. 2012. PMID: 22198217 Review.
-
Porcine Circovirus Type 2 (PCV2) Vaccines in the Context of Current Molecular Epidemiology.Viruses. 2017 May 6;9(5):99. doi: 10.3390/v9050099. Viruses. 2017. PMID: 28481275 Free PMC article. Review.
Cited by
-
Real-Time PCR Detection Patterns of Porcine Circovirus Type 2 (PCV2) in Polish Farms with Different Statuses of Vaccination against PCV2.Viruses. 2019 Dec 8;11(12):1135. doi: 10.3390/v11121135. Viruses. 2019. PMID: 31817963 Free PMC article.
-
Immune response in piglets orally immunized with recombinant Bacillus subtilis expressing the capsid protein of porcine circovirus type 2.Cell Commun Signal. 2020 Feb 11;18(1):23. doi: 10.1186/s12964-020-0514-4. Cell Commun Signal. 2020. PMID: 32046726 Free PMC article.
-
Chitosan microparticles loaded with yeast-derived PCV2 virus-like particles elicit antigen-specific cellular immune response in mice after oral administration.Virol J. 2014 Aug 20;11:149. doi: 10.1186/1743-422X-11-149. Virol J. 2014. PMID: 25141864 Free PMC article.
-
Generation in yeast of recombinant virus-like particles of porcine circovirus type 2 capsid protein and their use for a serologic assay and development of monoclonal antibodies.BMC Biotechnol. 2014 Dec 9;14:100. doi: 10.1186/s12896-014-0100-1. BMC Biotechnol. 2014. PMID: 25487652 Free PMC article.
-
Astragalus polysaccharides attenuate PCV2 infection by inhibiting endoplasmic reticulum stress in vivo and in vitro.Sci Rep. 2017 Jan 10;7:40440. doi: 10.1038/srep40440. Sci Rep. 2017. PMID: 28071725 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
